Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...

Weight loss injections are popular among adults, but a new study suggest they could be useful in fighting childhood obesity, ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having ... and no unexpected efficacy loss." Though Roche's statement is carefully couched to imply that getting ...